

CURRICULUM VITAE

PERSONAL INFORMATION

Family name, First name : **Rahman, Mohummad Aminur**
Date of birth : 02.01.1979
Sex : Male
Nationality : Norwegian
Phone : +4791385110
E-mail : Aminur.Rahman@uib.no
ORCID ID : 0000-0003-2207-5962

EDUCATION

2012 PhD
Department of Biosciences, University of Oslo, Norway
2007 Master
Department of Biotechnology, Lund University, Sweden
2003 Bachelor
Biotechnology Discipline, Khulna University, Bangladesh

CURRENT AND PREVIOUS POSITIONS

2020- Senior Researcher
Department of Oncology and Medical Physics, Haukeland University Hospital, Norway,
2015-2020 Researcher
Department of Biomedicine, University of Bergen, Norway
2012-2015 Post-doctoral Fellow
Department of Biomedicine, University of Bergen, Norway
2004-2005 Lecturer
Department of Biotechnology and Genetic Engineering, University of Development
Alternative, Bangladesh
2004-2005 Teaching and Research Assistant
Department of Biotechnology and Genetic Engineering, University of Development
Alternative, Bangladesh

FELLOWSHIPS AND AWARDS

2018 AACR-Takeda Oncology Scholar-in-Training Award 2018, American Association for
Cancer Research, USA. NOK 15000
2017 Det alminnelige medisinske forskningsfond, NOK 36000
2017 Legat for forskning av kreftsykdommer, NOK 45000
2017 Meltzer reisestipend, NOK 21000
2012-2015 Post-Doctoral Research fellowship at Department of Biomedicine, University of
Bergen, Norway
2007-2012 PhD fellowship from Faculty of Mathematics and Natural Sciences, University of
Oslo, Norway
2007 Summer scholarship from Lund University, Sweden
1997-2001 Undergraduate Merit Scholarship from Khulna University, Bangladesh

SUPERVISION OF GRADUATE STUDENTS AND RESEARCH FELLOWS

2012- 4 Master Students
Department of Biomedicine, University of Bergen, Norway

TEACHING ACTIVITIES

2023- MEDOD2, Undergraduate course / Second Semester Medicine and Dentistry
Department of Biomedicine, University of Bergen, Norway
2007-2012 Teaching Assistant – MBV2020 - Laboratory course in biochemistry and molecular
biology, Department of Molecular Biosciences, University of Oslo, Norway
2007-2012 Teaching Assistant – MBV4020 - Methods in molecular biology and biochemistry II,
Department of Molecular Biosciences, University of Oslo, Norway
2002-2005 Lecturer, Bachelor level Course: Biochemistry I and II, Molecular Biology I and II and
pharmacology. Department of Biotechnology and Genetic Engineering, University of
Development Alternative, Bangladesh

COMMISSIONS OF TRUST

- 2022- Review Editor in Cancer Immunity and Immunotherapy
Frontiers, Switzerland
- 2022- Review Editor in Cell Death and Survival
Frontiers, Switzerland
- 2022- Review Editor in Molecular Neurobiology
Springer Nature, United Kingdom

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

- 2021- Member, Society of Natural Immunity (SNI), Norway
- 2018- Member, Hjernesvulstforeningen, Norway
- 2018- Member, Society of Neuro-Oncology (SNO), USA
- 2018- Associate Member, American Association for Cancer Research (AACR), USA

DISSEMINATION ACTIVITIES

- 2019 Forskningsdagene with Brain Tumor Society Norway, University of Bergen, Norway
- 2021 Koronapandemien rammer kreftforskning, article in forskersonen.no

COURSES

- 2020 UPED639 Team-Based Learning, UNIPED: University of Bergen
- 2023 Introduction to GCP for site Staff, GCP-enhederne i Danmark

PUBLICATIONS

- The total number of publications during the career:
 - In peer reviewed journals: 21 (6 first author, 1 co-senior, H-index 12 Web of science)
 - In peer reviewed conference proceedings: 14
 - Book Chapter: 1
 - Total Citation until August 2023: 592 (Google Scholar)

List of major publications in major national or international peer-reviewed journals

1. Blakstad H, Brekke J, **Rahman MA**, Arnesen VS, Miletic H, Brandal P, et al. (2023) Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. *PLoS ONE* 18(2): e0281166. <https://doi.org/10.1371/journal.pone.0281166>
2. Hannisdal MH, Goplen D, Alam S, Haasz J, Oltedal L, **Rahman MA**, Rygh CB, Lie SA, Lundervold A, Chekenya M. Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI. *Neurooncol Adv.* 2023 Apr 13;5(1):vdad037. doi: 10.1093/noajnl/vdad037.
3. **Rahman MA**, Engelsen AST, Sarowar S, Bindsbøll C, Birkeland E, Goplen D, Lotsberg ML, Knappskog S, Simonsen A, Chekenya M. Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway. *Front Cell Dev Biol.* 2022 Dec 22;10:1022191. doi: 10.3389/fcell.2022.1022191.
4. Schneider M, Vollmer L, Potthoff AL, Ravi VM, Evert BO, **Rahman MA**, Sarowar S, Kueckelhaus J, Will P, Zurhorst D, Joseph K, Maier JP, Neidert N, d'Errico P, Meyer-Luehmann M, Hofmann UG, Dolf A, Salomoni P, Güresir E, Enger PØ, Chekenya M, Pietsch T, Schuss P, Schnell O, Westhoff, Jürgen Beck M, Vatter H, Waha A, Herrlinger U, Heiland DH. Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. *Neuro Oncol.* 2021 Apr 17;noab092.
5. **Rahman MA**, Brekke J, Arnesen V, Waha A, Herfindal L, Rygh CB, Bratland E, Brandal P, Haasz J, Oltedal L, Miletic H, Lundervold A, Lie SA, Goplen D, Chekenya M. Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes. *Immunity, Immunology and Disease*, 2020 Sep;8(3):342-359. doi: 10.1002/iid3.315. Epub 2020 Jun 24.
6. Leiss L, Mega A, Olsson Bontell T, Nistér M, Smits A, Corvigno S, **Rahman MA**, Enger PØ, Miletic H, Östman A. Platelet-derived growth factor receptor α /glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients. *Glia.* 2020 May;68(5):979-988. doi: 10.1002/glia.23756. Epub 2019 Nov 26.
7. **Rahman MA**, Gras Navarro A, Brekke J, Engelsen A, Bindsbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, Lie SA, Gjertsen BT, Selheim F, Enger PØ, Simonsen A, Chekenya M. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. *Br J Cancer.* 2019 Aug 15. doi: 10.1038/s41416-019-0551-1.

8. Gras Navarro A, Espedal H, Joseph JV, Trachsel-Moncho L, Bahador M, Gjertsen BT, Kristoffersen EK, Simonsen A, Miletic H, Enger PØ, ***Rahman MA**, *Chekenya M. Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. *Cancers (Basel)* **2019**; Jul 17;11(7). 1 ***Co-correspondence**
9. Haspels H, **Rahman MA**, Joseph JV, Gras Navarro A and Chekenya M. Glioblastoma stem-like cells are more susceptible than differentiated cells to NK cell lysis mediated through KIR-HLA ligand mismatch and activation receptor-ligand interactions. *Frontiers in Immunology* **2018**; 9: 1345.:
10. Bahador M, Gras Navarro, **Rahman MA**, Dominguez-Valentin, Sarowar S, Ulvedstad E, Njølstad G, Enger PØ, Lie SA, Kristoffersen EK, Bratland E, Chekenya M. Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. *Oncolmmunology* **2017**; 6(8): e1336272.:
11. Leiss L, Mutlu E, Øyan A, Yan T, Tsinkalovsky O, Sleire L, Petersen K, **Rahman MA**, Johannessen M, Mitra SS, Jacobsen HK, Talasila KM, Miletic H, Jonassen I, Li X, Brons NH, Kalland KH, Wang J, Enger PØ. Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts. *BMC Cancer*. 2017 Feb 7;17(1):108. doi: 10.1186/s12885-017-3109-8.
12. Dominguez Valentin M*, Gras Navarro A*, **Rahman AM***, Kumar S, Retière C, Ulvestad E, Kristensen V, Lund-Johansen M, Lie BA, Enger PØ, Njølstad G, Kristoffersen E, Lie SA, Chekenya M. Identification of a natural killer cell receptor allele that prolongs survival of cytomegalovirus-positive glioblastoma patients. *Cancer Res*. **2016** Jul 12. pii: canres.1162. 2016. ***equally contributed**.
13. Netland IA, Førde HE, Sleire L, Leiss L, **Rahman MA**, Skeie BS, Gjerde CH, Enger PØ, Goplen D. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. *BMC Cancer*. 2016 Aug 19;16:657. doi: 10.1186/s12885-016-2712-4.
14. Netland IA, Førde HE, Sleire L, Leiss L, **Rahman MA**, Skeie BS, Miletic H, Enger PØ, Goplen D. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats. *J Neurooncol*. 2016 Aug;129(1):57-66. doi: 10.1007/s11060-016-2158-1. Epub 2016 Jun 9.
15. **Rahman MA**, Kristiansen PE, Veiseth SV, Andersen JT, Yap KL, Zhou MM, Sandlie I, Thorstensen T, Aalen RB. The arabidopsis histone methyltransferase SUV4 binds ubiquitin via a domain with a four-helix bundle structure. *Biochemistry*. 2014 Apr 8;53(13):2091-100.
16. Kumpf R, Thorstensen T, **Rahman MA**, Heyman J, Nenseth HZ, Lammens T, Herrmann U, Swarup R, Veiseth SV, Emberland G, Bennett MJ, De Veylder L, Aalen RB. The ASH1-RELATED3 SET-domain protein controls cell division competence of the meristem and the quiescent center of the Arabidopsis primary root. *Plant Physiol*. 2014 Oct;166(2):632-43. doi: 10.1104/pp.114.244798. Epub 2014 Jul 17.
17. Veiseth SV, **Rahman MA**, Yap KL, Fischer A, Egge-Jacobsen W, Reuter G, Zhou M, Aalen, Reidunn B, Thorstensen T, & Qu L. (2011). The SUV4 Histone Lysine Methyltransferase Binds Ubiquitin and Converts H3K9me1 to H3K9me3 on Transposon Chromatin in Arabidopsis. *PLOS Genetics*., 7(3). <https://doi.org/10.1371/journal.pgen.1001325>
18. Hoppmann V, Thorstensen T, Kristiansen PE, Veiseth SV, **Rahman MA**, Finne K, Aalen RB, Aasland R. The CW domain, a new histone recognition module in chromatin proteins. *EMBO J*. 2011 May 18;30(10):1939-52. doi: 10.1038/emboj.2011.108.
19. **Rahman MA**, Bachar SC, Rahmatullah M. Analgesic and antiinflammatory activity of methanolic extract of *Acalypha indica* Linn. *Pak J Pharm Sci*. 2010 Jul;23(3):256-8.
20. Rahmatullah, M., Hasan, M.N., **Rahman, M.A.**, Ali, A.H.M.Z., Nahar, N., Jahan, R., Khatun, A., Ahmed, R., Ahsan, S. and Nasrin, D. (2010) 'School children's intellectual function when exposed to drinking water containing arsenic at Madartola (an arsenic affected area) in Bangladesh', *Advances in Environmental Biology*, May, 172+.
21. Rahmatullah, M., Das, N.K., **Rahman, M.A.**, Sultana, T., Jahan, R., A Preliminary study on co-cultivation of Mozambique tilapia (*Oreochromis mossambicus*) with bronze featherback (*Notopterus notopterus*) in shallow homestead ponds. *Indian Journal of Fisheries*, Volume 56, Issue 1, January 2009, Pages 43-45

Book Chapter

1. Leiss, L., Mutlu, E., **Rahman, M. A.**, Nilsen, M. H., & Enger, P. Øyvind. (n.d.). Tumor–Host Interactions in Malignant Gliomas. In *Biomarkers of the Tumor Microenvironment*. (2nd ed., pp. 509–518). Springer International Publishing AG. https://doi.org/10.1007/978-3-030-98950-7_30

Conference proceedings

1. Goplen, D., **Rahman, M. A.**, Brandal, P., Solheim, T. S., Brekke, J., Arnesen, V. S., Oltedal, L., Simonsen, A., Waha, A., Marienhagen, K., Haasz, J., Miletic, H., Lie, S. A., & Chekenya, M. (2023). BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology.*, 41(16_suppl), 2019–2019. https://doi.org/10.1200/JCO.2023.41.16_suppl.2019
2. Hannisdal, M., Goplen, D., Alam, S., Haasz, J., Oltedal, L., **Rahman, M.**, Rygh, C., Lie, S., Lundervold, A., & Chekenya, M. (2023). PD-0316 Deep learning tumor segmentation for target delineation in glioblastoma using multi-parametric MRI. *Radiotherapy and Oncology.*, 182, S251–S252. [https://doi.org/10.1016/S0167-8140\(23\)08847-3](https://doi.org/10.1016/S0167-8140(23)08847-3)
3. Goplen, D., **Rahman, M. A.**, Brekke, J., Arnesen, V., Simonsen, A., Waha, A., Marienhagen, K., Oltedal, L., Haasz, J., Miletic, H., Solheim, T. S., Brandal, P., Lie, S. A., & Chekenya, M. (2022). Abstract CT114: BORTEM-17 - phase IB/II single arm, non-randomized controlled multicenter study investigating whether sequential bortezomib and temozolomide is safe and effective in recurrent GBM with unmethylated MGMT promoter. *Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research*, 82(12_Supplement), CT114–CT114. <https://doi.org/10.1158/1538-7445.AM2022-CT114>
4. Arnesen, V. S., Suntharalingam, S., Matuszek, Z., Zaneta, Sarowar, S., Knappskog, S., Lie, S. A., Liu, D. R., **Rahman, M. A.**, & Chekenya, M. (2022). Abstract 3996: A novel 13-basepair deletion in CSPG4/NG2 abrogates protein expression, glioblastoma proliferation and invasion in vitro and in vivo in mice. *Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research*, 82(12_Supplement), 3996–3996. <https://doi.org/10.1158/1538-7445.AM2022-3996>
5. Goplen, D., **Rahman, M. A.**, Brekke, J., Arnesen, V. S., Simonsen, A., Waha, A., Marienhagen, K., Oltedal, L., Haasz, J., Miletic, H., Solheim, T. S., Brandal, P., Lie, S. A., & Chekenya, M. (2022). Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549). *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology.*, 40(16_suppl), TPS2081–TPS2081. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS2081
6. Blakstad, H., Brekke, J., **Rahman, M. A.**, Arnesen, V. S., Brandal, P., Lie, S. A., Chekenya, M., & Goplen, D. (2021). P14.65 Survival in a consecutive series of 467 glioblastoma patients: impact of prognostic factors and recurrent treatment at two independent institutions. *Neuro-Oncology.*, 23(Supplement_2), ii50–ii50. <https://doi.org/10.1093/neuonc/noab180.173>
7. Goplen, D., **Rahman, M. A.**, Arnesen, V. S., Brekke, J., Simonsen, A., Andreas, W., Marienhagen, K., Oltedal, L., Haasz, J., Miletic, H., Solheim, T. S., Brandal, P., Lie, S. A., & Chekenya, M. (2021). P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549). *Neuro-Oncology.*, 23(Supplement_2), ii39–ii39. <https://doi.org/10.1093/neuonc/noab180.135>
8. **Rahman, M. A.**, Navarro, A. G., Brekke, J., Bindesbøll, C., Engelsen, A., Sarowar, S., Bahador, M., Gjertsen, B. T., Goplen, D., Enger, P. Ø, Selheim, F., Simonsen, A., & Chekenya, M. (2018). Abstract 2928: Bortezomib sensitizes glioblastoma with unmethylated MGMT promoter to temozolomide-chemotherapy through MGMT depletion and abrogated autophagy flux. *Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research*, 78(13_Supplement), 2928–2928. <https://doi.org/10.1158/1538-7445.AM2018-2928>
9. Navarro, A. G., **Rahman, A.**, Bahador, M., & Enger, M. C. (2017). Abstract LB-195: Bortezomib sensitizes glioblastoma for NK cell immunotherapy. *Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research*, 77(13_Supplement), LB–195–LB–195. <https://doi.org/10.1158/1538-7445.AM2017-LB-195>
10. **Rahman, M. A.**, Liess, L., Lellahi, M. S., Gjerde, C. H., Saed, H. S., Mutlu, E., Zhu, H., Wang, J., & Enger, P. Øyvind. (2015). Abstract 2101: The transcription factor POU3F2 is expressed in human gliomas and promotes tumorigenesis in vivo. *Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research*, 75(15_Supplement), 2101–2101. <https://doi.org/10.1158/1538-7445.AM2015-2101>
11. Gjerde, C. H., Mutlu, E., Leiss, L., Kristensen, B. W., **Rahman, M. A.**, & Enger, P. Øyvind. (2015). Abstract 1560: FGFR4 is expressed in the tumor and stromal compartments of human gliomas of all grades and histologies. *Cancer Research : a Monthly Journal of Articles and Abstracts Reporting*

- Cancer Research: the Official Organ of the American Association for Cancer Research*, 75(15_Supplement), 1560–1560. <https://doi.org/10.1158/1538-7445.AM2015-1560>
12. **Rahman, M. A.**, Leiss, L., Lellahi, M. S., Gjerde, C. H., Saed, H. S., Mutlu, E., & Enger, P. O. (2014). CS-28 * THE TRANSCRIPTION FACTOR POU3f2 UNIFORMLY EXPRESS IN HUMAN GLIOMAS AND PROMOTES TUMORIGENESIS AND OVERALL GROWTH RATE IN VIVO. *Neuro-Oncology.*, 16(Suppl 5), v57–v57. <https://doi.org/10.1093/neuonc/nou242.28>
 13. **Rahman, M. A.**, Leiss, L., Saed, H. S., Gjerde, C. H., Lellahi, M. S., Mutlu, E., & Enger, P. Øyvind. (2014). Abstract LB-75: Oct7 is expressed in human gliomas and correlates with malignancy grade. *Cancer Research: a Monthly Journal of Articles and Abstracts Reporting Cancer Research: the Official Organ of the American Association for Cancer Research*, 74(19_Supplement), LB–75–LB–75. <https://doi.org/10.1158/1538-7445.AM2014-LB-75>
 14. **Rahman MA**, Sandvik SV, Thorstensen T, Davies W, Aalene RB. Arabdiopsis SET-domain Proteins with Different Histone Methyltransferase Activity. In ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES 2009 Jan 1 (Vol. 65, pp. S157-S158). 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND: INT UNION CRYSTALLOGRAPHY.

Aminur Rahman

Mohummad Aminur Rahman, PhD